The Filing Desk

BioRestorative Therapies vs Connect Biopharma

BioRestorative Therapies BRTX · Connect Biopharma CNTB · Biotechnology

BioRestorative Therapies reported revenue of $0 million in fiscal 2025, 4.0 times Connect Biopharma's $0 million in fiscal 2025. BioRestorative Therapies' revenue fell 10.3% in its latest year, and Connect Biopharma's fell 99.8%. BioRestorative Therapies had an operating margin of -4350.1%, against -90740.6% at Connect Biopharma. Free cash flow was −$11 million at BioRestorative Therapies and −$52 million at Connect Biopharma.

Side by side

BioRestorative TherapiesConnect Biopharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth−10.3%−99.8%
Revenue growth a year, last 5 years32.0%—
Gross margin93.4%—
Operating margin−4,350.1%−90,740.6%
Net margin−3,959.4%−86,687.5%
Free cash flow−$11M−$52M
Free cash flow margin−3,031.7%−80,687.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.8%0.8%
Last close$1.31$0.63
P/E at the last close——
Insider trades, last 12 months—bought $4.4 million, sold $0
Piotroski F-score—1 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BioRestorative TherapiesConnect Biopharma
Operating margin
Percent of revenue
BioRestorative TherapiesConnect Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioRestorative TherapiesConnect Biopharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioRestorative Therapies and Connect Biopharma pages.